Table 1.
General characteristics of patients.
| Variable | Median (range or absolute frequency) |
|---|---|
| Age (year) | 54 (27–80) |
| Gender (female) | 42 (40.8%) |
| Tumor location (pyloric antrum) | 50 (48.5%) |
| HER-2 (positive) | 28 (27.2%) |
| TNM stage I-II/III/IV | 20 (19.4%)/25 (24.3%)/58 (56.3%) |
| Metastasis (yes) | 58 (56.3%) |
| RDW (%) | 13.4 (11.5–32.7) |
| WBC (g/L) | 5.69 (3.03–12.81) |
| MO (g/L) | 0.42 (0.11–1.46) |
| NLR | 2.54 (1.00–32.28) |
| CA125 (U/mL) | 26.6 (4.0–4853.6) |
| CA199 (U/mL) | 11.9 (2.0–1200.0) |
| CEA (μg/L) | 2.4 (0.5–12854.0) |
| RDW + NLR 0/1/2 | 38 (36.9%)/37 (35.9%)/28 (27.2%) |
| Overall survival | 8.9 (0.9–51.7) |
| Progression-free survival | 6.1 (0.9–51.7) |
RDW: red cell distribution width; NE: neutrophil; MO: monocyte; PDW: platelet distribution width; NLR: neutrophil-to-lymphocyte ratio; RDW + NLR: combination of red blood cell distribution width and neutrophil-to-lymphocyte ratio.